Plasma Ropivacaine Concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

Short Title: Ropivacaine concentration after rectus sheath blocks

1. Author: Morito Wada
   - Title: MD.
   - Affiliation: Hirosaki University Graduate School of Medicine
   - Email: masuika@cc.hirosaki-u.ac.jp
   - Conflict of Interest: None
   - Attestation: Study design, Data Collection, Data Analysis, Manuscript Preparation

2. Author: Masato Kitayama
   - Title: MD, PhD
   - Affiliation: Hirosaki University Graduate School of Medicine
   - Email: kitasan@cc.hirosaki-u.ac.jp
   - Conflicts: None
   - Attestation: Study design, Conduct of Study, Data Collection, Data Analysis, Manuscript Preparation

3. Author: Hiroshi Hashimoto
   - Title: MD, PhD
   - Affiliation: Hirosaki University Graduate School of Medicine
   - Email: masuika@cc.hirosaki-u.ac.jp
   - Conflicts: None
   - Attestation: Data Collection

4. Author: Tsuyoshi Kudo
   - Title: PhD
   - Affiliation: Hirosaki University Graduate School of Medicine
   - Email: masuika@cc.hirosaki-u.ac.jp
5. Author: Mihoko Kudo

- Title: PhD
- Affiliation: Hirosaki University Graduate School of Medicine
- Email: masuika@cc.hirosaki-u.ac.jp
- Conflicts: None
- Attestation: Data Collection, Data Analysis

6. Author: Norikazu Takada

- Title: MD
- Affiliation: Hirosaki University Graduate School of Medicine
- Email: masuika@cc.hirosaki-u.ac.jp
- Conflicts: None
- Attestation: Data Collection

7. Author: kazuyoshi Hirota

- Title: MD, PhD, FRCA.
- Affiliation: Hirosaki University Graduate School of Medicine
- Email: hirotak@cc.hirosaki-u.ac.jp
- Conflicts: None
- Attestation: Study Design, Conduct of Study, Data Analysis, Manuscript Preparation

Name of Department(s) and Institution(s): Department of Anesthesiology, Hirosaki University Graduate School of Medicine,

Hirosaki, 036-8562, Japan.

Financial Support: None

Corresponding Author: Masato Kitayama

Department of Anesthesiology, Hirosaki University Graduate School of Medicine,


kitasan@cc.hirosaki-u.ac.jp
Did a Section Editor solicit this submission? Name: None
Abstract

A rectus sheath block can provide postoperative analgesia for midline incisions. However, information regarding the pharmacokinetics of local anesthetics used in this block is lacking. In this study, we detail the time course of ropivacaine concentrations following this block. Thirty-nine patients undergoing elective lower abdominal surgery were assigned to three groups receiving rectus sheath block with 20mL of different concentrations of ropivacaine. Peak plasma concentrations (C_max) were dose-dependent, and there were no significant differences in the times (T_max) to C_max. The present data also suggested a slower absorption kinetics profile for ropivacaine following rectus sheath block than other compartment blocks.

Number of words: 100
Introduction

The rectus sheath block was first described by Schleich\(^1\) to provide relaxation of the anterior abdominal wall for intra-abdominal surgery. This block can also provide postoperative analgesia for procedures utilizing a midline incision\(^2\)-\(^6\) by acting on the terminal branches of the 7th-11th intercostal nerves within the rectus sheath, although it requires relatively high volume of local anesthetics. Recently, ultrasound-guided regional anesthesia and analgesia has improved the placement of local anesthetics and reduced inadvertent vessel or peritoneal puncture in pediatric patients\(^7\). However, information regarding the potential for local anesthetic systemic toxicity with this block is lacking. In this study, we detail the pharmacokinetics of various concentrations of ropivacaine following rectus sheath block for lower abdominal surgery.
Methods

With the approval of our University ethics committee and written informed consent, 39 adult patients (ASA 1-2) undergoing elective lower abdominal surgery with midline incisions were enrolled into this study. Patients with bleeding tendency or coagulation disorder were excluded. Laparotomy was performed by the same surgical team. All patients were premedicated orally with diazepam 4-10 mg and roxatidine 75 mg 90 min before the induction of anesthesia. Anesthesia was induced with propofol 1-1.5mg/kg and fentanyl 100 μg. Following muscle relaxation with intravenous vecuronium 0.1mg/kg, endotracheal intubation was performed. Anesthesia was maintained with propofol 5-10 mg/kg/hr and fentanyl (total 10 μg/kg) along with an oxygen/air mixture (FiO₂=0.4). Muscle relaxation was maintained with vecuronium. Propofol infusion rate was altered to maintain the bispectral index (BIS) between 40 and 50 during anesthesia.

The patients were randomly assigned to three groups (n=13 each) receiving rectus sheath block with 20 mL of different concentrations of ropivacaine: 0.75 (Group 0.75), 0.5 (Group 0.5) and 0.25 % (Group 0.25) to determine pharmacokinetics. Following general anesthesia, a bilateral ultrasound-guided rectus sheath block was performed. Ten milliliters of the study drug solution was injected symmetrically on each side. We utilized a real-time and in-plane needle insertion technique in which the needle and spread of local anesthetic was fully visualized using a portable ultrasound unit and a 6-12MHz linear probe (MicroMaxx, SomoSite™, Bothell, WA, USA) (Figure 1). The injection was performed in the same manner on the opposite side.

To determine plasma concentrations of ropivacaine, arterial blood (3 mL) was drawn from a radial artery catheter before and 15, 30, 45, 60, 90, 120 and 180 min after completion of bilateral
rectus sheath blocks. Blood samples were centrifuged to separate the plasma, which was stored at -20°C until assay. Plasma ropivacaine concentrations were analyzed by gas chromatography with mass spectrometry (GC/MS) previously described by Björk et al.8 with tetracaine as the internal standard. Tetracaine was only used as an internal standard, was not administered to patients. The retention times for tetracaine and ropivacaine were 4.9 min and 4.7 min, respectively. The limit of determination for ropivacaine was 10 ng/mL. The within-day (intraassay) coefficient of variation of the assay varied from 3.7% at 500 ng/mL to 3.1% at 1000 ng/mL. Sample size of at least 12 patients per group was needed to have a power of 80%, a SD of 0.5 μg/mL and significance at the two-sided 5% level, and on the basis of previous studies9, we expected a difference in mean Cmax of about 0.6 μg/mL between each group. Data are presented as mean±SD. Statistical analysis was performed using two-way repeated measures ANOVA with Dunnett’s post-hoc test.
Results
Patient characteristics were not different among the three groups (Table 1). Changes in plasma ropivacaine concentrations for the first 180 min following ultrasound-guided rectus sheath block are shown in Figure 2.

The Cmax was significantly different between groups 0.25 and 0.75 (p<0.001), and 0.25 and 0.5 (p<0.05), while there were no statistically significant differences in Tmax among the groups (Table 2). Serious adverse events were not observed following rectus sheath block in any patient. The highest individual plasma concentration was 2.88 µg/ml observed 45 min after rectus sheath block with 0.75% ropivacaine.
Discussion

This is the first report of the pharmacokinetics of ropivacaine after rectus sheath block. In general, compartment blocks tend to show rapid absorption kinetics, because the absorption rate is relative to the vascularity of the tissue, concentration of local anesthetic and the spread of injected solution. In the present study, the times to peak concentration of ropivacaine following rectus sheath block was similar in duration to those of ilioinguinal/iliohypogastric nerve blocks reported previously \(^{10-12}\), but delayed compared to those of paravertebral block\(^9\), intercostal blocks\(^{13}\) and transversus abdominis plane block\(^{14-15}\). The rectus muscle is supplied by the supra- and infra-epigastric arteries. Although this represents a highly vascular area, the local anesthetic is actually deposited in the relatively avascular fascial plane posterior to the muscle. This location for the deposition of local anesthetic may contribute to the slow vascular uptake. The threshold concentration for critical ropivacaine toxicity is not well established. Several reports for severe cardiovascular toxicity (cardiac arrest, severe bradycardia etc.) after ropivacaine used have been documented, including measured plasma concentration data. In such cases of blood sampling, timing was within 45 minutes after injection and plasma concentrations ranged from 3.2 to 3.6 \(\mu g/mL\)\(^{16-17}\). In this study, the highest individual plasma concentration was below this range. Furthermore most of our concentrations approach those associated with only mild CNS symptoms “levels ranging from 1 to 2 \(\mu g/mL\), which were reported by Scott and colleagues\(^{18}\)”. In conclusion, the present data demonstrated that plasma ropivacaine concentrations following ultrasound-guided rectus sheath block (0.25-0.75%; 20mL) increase dose dependently and do not reach critical toxic levels. Since the volume of the ropivacaine injection limited to 10mL per side and not based on mg/kg basis, the blood concentration data
reflecting the safety of this technique may not apply to patients with a larger body mass index than our study population.
### Tables

Table 1. Patient characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Ropivacaine group</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.25%</td>
<td>0.5%</td>
<td>0.75%</td>
</tr>
<tr>
<td>No of patients</td>
<td>13</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Gender (Male/Female)</td>
<td>9/4</td>
<td>6/7</td>
<td>8/5</td>
</tr>
<tr>
<td>Age (y)</td>
<td>58[19-87]</td>
<td>59[37-76]</td>
<td>58[26-76]</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162±12</td>
<td>159±8</td>
<td>161±10</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>58±8</td>
<td>52±8</td>
<td>50±13</td>
</tr>
<tr>
<td>Duration of Surgery (min)</td>
<td>134±51</td>
<td>114±61</td>
<td>151±45</td>
</tr>
</tbody>
</table>

Data are expressed as Mean±S.D. or Mean[range]. There are no significant differences between groups.
Table 2. Maximum plasma concentration ($C_{\text{max}}$) and time ($T_{\text{max}}$) to reach $C_{\text{max}}$ after rectus sheath block with 0.75, 0.5 or 0.25% of ropivacaine.

<table>
<thead>
<tr>
<th>Ropivacaine group</th>
<th>0.25%</th>
<th>0.5%</th>
<th>0.75%</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ (µg.mL$^{-1}$)</td>
<td>0.50±0.21</td>
<td>1.11±0.44*</td>
<td>1.51±0.82**</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (min)</td>
<td>49.6±21.6</td>
<td>48.5±28.8</td>
<td>38.1±14.5</td>
</tr>
</tbody>
</table>

Mean±SD (n=13 per group).

*p<0.05, **p<0.01 compared with group 0.25%.
Figures and Illustrations

Figure 1. Wada M, et al.
Figure 2. Wada M, et al
Figure Legends

Figure 1. Cross-sectional scan of rectus abdominis muscle during rectus sheath block. Injection sites were infra-umbilical (1-2cm below the umbilicus). White arrows indicate spread of the ropivacaine in the target, between the rectus abdominis muscle and the posterior sheath. Black arrow indicates the tip of the needle.

Figure 2. Mean arterial plasma concentration of ropivacaine after administration of 20ml of either 0.25, 0.5 or 0.75% ropivacaine for bilateral rectus sheath block. Data are presented mean ± SD (n=13 per group)
References


10. Ala-Kokko TI, Karinen J, Räihä E, Kiviluoma K, Alahuhta S. Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. Br J Anaesth. 2002; 89: 438-41


Author Conflict of Interest Checklist

To facilitate disclosure, each author must answer the following questions. If you answer any question “yes,” add explanatory information below that question. You may edit this form as required to facilitate disclosure. Please append the completed form to your manuscript on the initial submission. It is not required for revisions unless the COI has changed or additional authors have been added to the paper.

The Journal encourages full disclosure. The Journal recognizes that conflict-of-interest is very common and in some settings is unavoidable. Only in exceptional cases does the Journal consider author conflict-of-interest in the peer review process. Please see the Guide for Authors for additional instructions.

Manuscript Title: Plasma ropivacaine concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

First Author: Morito Wada MD
Disclosing Author: Morito Wada, MD

1. Have you or a close relative received money, gifts, or other compensation from any organization, institution, or business that may be affected financially by your publication? Examples include speaker fees, consulting fees, honoraria, travel, gifts, or research funding. Yes ☐ No ☑

2. Have you or a close relative been employed by an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

3. Have you or a close relative been in a supervisory position, e.g., Officer or Director of an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

4. Do you or a close relative hold stocks, investments, or other financial interests (excluding diversified mutual funds) in an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

5. Could the findings of this publication directly or indirectly affect your compensation? Yes ☐ No ☑

6. Are there any other potential conflicts or relevant competing interests that should be known by the Editor? Yes ☐ No ☑
Author Conflict of Interest Checklist

To facilitate disclosure, each author must answer the following questions. If you answer any question “yes,” add explanatory information below that question. You may edit this form as required to facilitate disclosure. Please append the completed form to your manuscript on the initial submission. It is not required for revisions unless the COI has changed or additional authors have been added to the paper.

The Journal encourages full disclosure. The Journal recognizes that conflict-of-interest is very common and in some settings is unavoidable. Only in exceptional cases does the Journal consider author conflict-of-interest in the peer review process. Please see the Guide for Authors for additional instructions.

Manuscript Title: Plasma ropivacaine concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

First Author: Morito Wada MD
Disclosing Author: Masato Kitayama, MD, PhD

1. Have you or a close relative received money, gifts, or other compensation from any organization, institution, or business that may be affected financially by your publication? Examples include speaker fees, consulting fees, honoraria, travel, gifts, or research funding. Yes ☐ No ☑

2. Have you or a close relative been employed by an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

3. Have you or a close relative been in a supervisory position, e.g., Officer or Director of an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

4. Do you or a close relative hold stocks, investments, or other financial interests (excluding diversified mutual funds) in an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

5. Could the findings of this publication directly or indirectly affect your compensation? Yes ☐ No ☑

6. Are there any other potential conflicts or relevant competing interests that should be known by the Editor? Yes ☐ No ☑
Author Conflict of Interest Checklist

To facilitate disclosure, each author must answer the following questions. If you answer any question "yes," add explanatory information below that question. You may edit this form as required to facilitate disclosure. Please append the completed form to your manuscript on the initial submission. It is not required for revisions unless the COI has changed or additional authors have been added to the paper.

The Journal encourages full disclosure. The Journal recognizes that conflict-of-interest is very common and in some settings is unavoidable. Only in exceptional cases does the Journal consider author conflict-of-interest in the peer review process. Please see the Guide for Authors for additional instructions.

Manuscript Title: Plasma ropivacaine concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

First Author: Morito Wada MD
Disclosing Author: Hiroshi Hashimoto, MD, PhD

1. Have you or a close relative received money, gifts, or other compensation from any organization, institution, or business that may be affected financially by your publication? Examples include speaker fees, consulting fees, honoraria, travel, gifts, or research funding. Yes ☐ No ☑

2. Have you or a close relative been employed by an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

3. Have you or a close relative been in a supervisory position, e.g., Officer or Director of an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

4. Do you or a close relative hold stocks, investments, or other financial interests (excluding diversified mutual funds) in an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

5. Could the findings of this publication directly or indirectly affect your compensation? Yes ☐ No ☑

6. Are there any other potential conflicts or relevant competing interests that should be known by the Editor? Yes ☐ No ☑
Author Conflict of Interest Checklist

To facilitate disclosure, each author must answer the following questions. If you answer any question “yes,” add explanatory information below that question. You may edit this form as required to facilitate disclosure. Please append the completed form to your manuscript on the initial submission. It is not required for revisions unless the COI has changed or additional authors have been added to the paper.

The Journal encourages full disclosure. The Journal recognizes that conflict-of-interest is very common and in some settings is unavoidable. Only in exceptional cases does the Journal consider author conflict-of-interest in the peer review process. Please see the Guide for Authors for additional instructions.

Manuscript Title: Plasma ropivacaine concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

First Author: Morito Wada, MD
Disclosing Author: Tsuyoshi Kudo, PhD

1. Have you or a close relative received money, gifts, or other compensation from any organization, institution, or business that may be affected financially by your publication? Examples include speaker fees, consulting fees, honoraria, travel, gifts, or research funding. Yes ☐ No ☑

2. Have you or a close relative been employed by an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

3. Have you or a close relative been in a supervisory position, e.g., Officer or Director of an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

4. Do you or a close relative hold stocks, investments, or other financial interests (excluding diversified mutual funds) in an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

5. Could the findings of this publication directly or indirectly affect your compensation? Yes ☐ No ☑

6. Are there any other potential conflicts or relevant competing interests that should be known by the Editor? Yes ☐ No ☑
Author Conflict of Interest Checklist

To facilitate disclosure, each author must answer the following questions. If you answer any question “yes,” add explanatory information below that question. You may edit this form as required to facilitate disclosure. Please append the completed form to your manuscript on the initial submission. It is not required for revisions unless the COI has changed or additional authors have been added to the paper.

The Journal encourages full disclosure. The Journal recognizes that conflict-of-interest is very common and in some settings is unavoidable. Only in exceptional cases does the Journal consider author conflict-of-interest in the peer review process. Please see the Guide for Authors for additional instructions.

Manuscript Title: Plasma ropivacaine concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

First Author: Morito Wada, MD
Disclosing Author: Mihoko Kudo, PhD

1. Have you or a close relative received money, gifts, or other compensation from any organization, institution, or business that may be affected financially by your publication? Examples include speaker fees, consulting fees, honoraria, travel, gifts, or research funding. Yes ☐ No ☑

2. Have you or a close relative been employed by an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

3. Have you or a close relative been in a supervisory position, e.g., Officer or Director of an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

4. Do you or a close relative hold stocks, investments, or other financial interests (excluding diversified mutual funds) in an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

5. Could the findings of this publication directly or indirectly affect your compensation? Yes ☐ No ☑

6. Are there any other potential conflicts or relevant competing interests that should be known by the Editor? Yes ☐ No ☑
Author Conflict of Interest Checklist

To facilitate disclosure, each author must answer the following questions. If you answer any question “yes,” add explanatory information below that question. You may edit this form as required to facilitate disclosure. Please append the completed form to your manuscript on the initial submission. It is not required for revisions unless the COI has changed or additional authors have been added to the paper.

The Journal encourages full disclosure. The Journal recognizes that conflict-of-interest is very common and in some settings is unavoidable. Only in exceptional cases does the Journal consider author conflict-of-interest in the peer review process. Please see the Guide for Authors for additional instructions.

Manuscript Title: Plasma ropivacaine concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

First Author: Morito Wada, MD
Disclosing Author: Norikazu Takada, MD

1. Have you or a close relative received money, gifts, or other compensation from any organization, institution, or business that may be affected financially by your publication? Examples include speaker fees, consulting fees, honoraria, travel, gifts, or research funding. Yes ☐ No ☑

2. Have you or a close relative been employed by an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

3. Have you or a close relative been in a supervisory position, e.g., Officer or Director of an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

4. Do you or a close relative hold stocks, investments, or other financial interests (excluding diversified mutual funds) in an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

5. Could the findings of this publication directly or indirectly affect your compensation? Yes ☐ No ☑

6. Are there any other potential conflicts or relevant competing interests that should be known by the Editor? Yes ☐ No ☑
Author Conflict of Interest Checklist

To facilitate disclosure, each author must answer the following questions. If you answer any question “yes,” add explanatory information below that question. You may edit this form as required to facilitate disclosure. Please append the completed form to your manuscript on the initial submission. It is not required for revisions unless the COI has changed or additional authors have been added to the paper.

The Journal encourages full disclosure. The Journal recognizes that conflict-of-interest is very common and in some settings is unavoidable. Only in exceptional cases does the Journal consider author conflict-of-interest in the peer review process. Please see the Guide for Authors for additional instructions.

Manuscript Title: Plasma ropivacaine concentrations after Ultrasound-guided Rectus Sheath Block in Patients Undergoing Lower Abdominal Surgery

First Author: Morito Wada, MD
Disclosing Author: Kazuyoshi Hirota, MD, PhD, FRCA

1. Have you or a close relative received money, gifts, or other compensation from any organization, institution, or business that may be affected financially by your publication? Examples include speaker fees, consulting fees, honoraria, travel, gifts, or research funding. Yes ☐ No ☑

2. Have you or a close relative been employed by an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

3. Have you or a close relative been in a supervisory position, e.g., Officer or Director of an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

4. Do you or a close relative hold stocks, investments, or other financial interests (excluding diversified mutual funds) in an organization, institution, or business that may be affected financially by your publication? Yes ☐ No ☑

5. Could the findings of this publication directly or indirectly affect your compensation? Yes ☐ No ☑

6. Are there any other potential conflicts or relevant competing interests that should be known by the Editor? Yes ☐ No ☑